CALR and essential thrombocythemia: In addition, for patients with ET, frequencies of three driver mutations in our study were similar to the results reported in the systematic review [3]: specifically, JAK2 V617F 28% versus 31%, CALR 8% versus 10%, and MPL 0% versus 2%, respectively.